Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPRelated productsBioactivityChemical infoStorage&SolubilityCalculator

KBP-089

Copy Product Info
🥰Excellent

Synonyms:

Catalog No. TP4342 Copy Product Info
🥰Excellent
KBP-089 is a dual agonist for both amylin (Amylin) and calcitonin receptor (CalcitoninReceptor). It contributes to weight reduction, reduced adipose tissue, and improved glucose tolerance in obese rats. KBP-089 also facilitates the clearance of lipid accumulation in the liver and muscles, enhancing glucose homeostasis and insulin sensitivity. This compound is applicable for research in obesity and type 2 diabetes.

KBP-089

Cas No. 1776112-67-4
Pack SizePriceUSA StockGlobal StockQuantity
10 mgInquiryInquiryInquiry
50 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
KBP-089 is a dual agonist for both amylin (Amylin) and calcitonin receptor (CalcitoninReceptor). It contributes to weight reduction, reduced adipose tissue, and improved glucose tolerance in obese rats. KBP-089 also facilitates the clearance of lipid accumulation in the liver and muscles, enhancing glucose homeostasis and insulin sensitivity. This compound is applicable for research in obesity and type 2 diabetes.
In vitro
KBP-089 (3 hours) effectively activates human CTR and AMY3-R in heterologous cell lines, with a pEC50 range of 8.7 to 9.9, and induces sustained receptor activation for up to 72 hours.
In vivo
KBP-089, administered subcutaneously, has been shown to effectively reduce body weight in rats on a high-fat diet when given at a dose of (5 μg/kg, daily or every other day for 15 days). A dose escalation from 0.625 to 40 μg/kg over six weeks leads to weight reduction and improved glucose tolerance. Additionally, a single dose ranging from 0.625 to 40 μg/kg can suppress calorie intake in a dose-dependent manner within 48 hours in fasted high-fat-diet-fed rats. Long-term administration (5-20 μg/kg, over 8 weeks) lowers blood glucose levels, enhances glucose tolerance, and increases insulin action in diabetic obese rats. At 2.5 µg/kg for 7 days, it reduces overall caloric intake and shifts food preference from chocolate to regular feed in normally-fed rats.
Chemical Properties
Molecular Weight3529.98
FormulaC148H242N46O48S3
Cas No.1776112-67-4
SmilesC([C@H](CC1=CC=C(O)C=C1)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC2=CN=CN2)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@@H](NC(=O)[C@H]3NC(=O)[C@]([C@@H](C)O)(NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(C)=O)CSSC3)[H])CCSC)=O)CC(C)C)=O)=O)CCCNC(=N)N)=O)CC(C)C)=O)CO)=O)CCC(N)=O)=O)CC(O)=O)=O)CC(C)C)=O)=O)CCCNC(=N)N)=O)CC(C)C)=O)CCC(N)=O)=O)[C@@H](C)O)=O)(=O)N4[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(=O)N5[C@H](C(N)=O)CCC5)C)=O)CC(N)=O)=O)C)=O)=O)C(C)C)=O)CC(O)=O)=O)[C@@H](C)O)=O)CCCCN)=O)CCC4
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 µL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
µL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: KBP-089 in vivo | KBP-089 in vitro | KBP-089 formula | KBP-089 molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.